Search - tctmd.com

Displaying 241 - 260 of 458

Sort: Relevancy | Date

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

June 19, 2017

Aspirin Use by Elderly Patients After Vascular Events Linked to More Bleeding, Especially GI Bleeds

News Daily News

Aspirin Use by Elderly Patients After Vascular Events Linked to More Bleeding, Especially GI Bleeds

Michael O'Riordan

June 14, 2017

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

News Daily News

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

May 11, 2017

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

News Daily News

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

May 04, 2017

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

News Daily News

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

May 03, 2017

If You Don’t Take Your Stroke Meds, This App Will Tell on You

News Daily News

If You Don’t Take Your Stroke Meds, This App Will Tell on You

April 18, 2017

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

News Daily News

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

March 28, 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presentation ACC 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presenter: Magnus Ohman

March 27, 2017

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Presentation ACC 2017

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Presenter: Jeff Weitz

March 20, 2017

RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest

News Conference News ACC 2017

RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest

Yael L. Maxwell

March 20, 2017

Live From Washington: ACC 2017, Day Two

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

March 18, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

March 18, 2017

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

March 14, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

TCTMD’s Top 10 Most Popular Stories for February 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2017

March 01, 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

News Conference News ISC 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

March 01, 2017

Rivaroxaban’s “Overwhelming” Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

February 08, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.